MARKET EYE-Pharma stocks fall on speculation over pricing policy
* Shares in Indian drugmakers fall on speculation the government's final decision on the pricing policy for the sector might be more disruptive than expected. * Local media reports suggest a panel of ministers has agreed to settle on a market-based pricing mechanism, as expected, but capping drug prices at a simple average price of brands as opposed to the initial proposal of using a weighted average. link.reuters.com/jur24t * The proposal, if finalised, would be "incrementally negative" for the sector, but the impact would vary from company to company, Nomura says in a note on Thursday. * The new proposal is likely to be more negative for Dr Reddy's , Glenmark and Cadila Healthcare, Nomura says. * Cipla falls 0.1 percent, while Ranbaxy Laboratories is down 0.9 percent. * Dr Reddy's Laboratories is flat, Glenmark Pharmaceuticals is up 3.9 percent and Cadila gains 2.2 percent. (firstname.lastname@example.org /; email@example.com/kaustubh.kulkarni@thoms onreuters.com /; firstname.lastname@example.org)
- Tweet this
- Share this
- Digg this
DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.
Trending On Reuters
India's largest carmaker Maruti Suzuki India Ltd posted a smaller-than-expected rise in profit for the third quarter, hit by one-off items including a jump in advertising costs, a higher tax rate and lower income from investments. Full Article | Full coverage